🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Annexon, Inc. ANNX R2K

Healthcare · Biotechnology · United States
https://www.annexonbio.com

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

READ MORE ›
$5.42
+165.69% 1Y

Market & Price

Market Cap
$888.03M
Current Price
$5.42
High / Low (52W)
$6.96 / $2.04
Beta
1.22

Valuation

Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$1.26
Price to Book
4.31
P/S
-
EV/EBITDA
-3.39
Dividend Yield
-

Profitability & Returns

ROCE
-92.11%
ROE
-87.65%
ROA
-45.29%
Profit Margin
0.00%
Op Margin
0.00%
EPS (Latest Qtr)
$-0.23
EPS (TTM)
$-1.20

Balance Sheet & Liquidity

Debt/Equity
0.12
Quick Ratio
6.26
Current Ratio
6.35
Debt
$25.43M
Total Assets
$277.57M
Current Assets
$242.19M
Working Capital
$199.56M

Ownership

Promoter Holding
0.47%
Chg in Prom Hold
0.00%
FII / Inst Holding
102.70%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
$688.44M
Total Revenue (TTM)
-
EBITDA
$-202.89M
Free Cash Flow
$-107.34M
Operating Cash Flow
$-183.10M
Shares Outstanding
163.84M
Gross Margin
0.00%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
-15.20%
Revenue (YoY)
-
Earnings (YoY)
-

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Earnings shrank at -15.2% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ANNX Annexon, Inc. R2K 5.42 - $888.03M - -92.11% -87.65% - -15.20%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
⚙Ad space

Quarterly Results

Figures in USD.

Metric Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue ------------------00000
Cost of Revenue -----------------------
Gross Profit -----------------------
Operating Expenses ------------------57.41M51.73M57.02M50.26M46.05M
Operating Income --8.22M-9.07M-12.46M-12.24M-15.59M-26.20M-31.37M-35.68M-35.43M-37.41M-36.07M-41.24M-37.69M-34.78M-28.57M-33.58M--57.41M-51.73M-57.02M-50.26M-46.05M
EBITDA -------------------56.69M-51.11M-56.47M-49.72M-45.40M
Interest Expense -----------------------
Pretax Income -------------------54.36M-49.16M-54.92M-48.26M-44.14M
Tax Provision -----------------------
Net Income -8.65M-9.40M-10.19M-12.34M-12.24M-15.64M-26.06M-31.29M-35.60M-35.37M-37.14M-35.05M-38.68M-35.19M-32.48M-25.18M-29.61M--54.36M-49.16M-54.92M-48.26M-44.14M
Diluted EPS --------0.82-0.93-0.92-0.96-0.51-0.52-0.47-0.43-0.21-0.23--0.37-0.34-0.37-0.28-0.23
R&D Expense -5.99M7.09M10.22M9.29M11.78M20.70M24.57M27.58M27.00M29.11M27.86M32.34M30.25M27.89M20.96M25.03M30.11M48.18M44.16M49.70M-35.79M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue ---0000
Cost of Revenue -------
Gross Profit -------
Operating Expenses ---145.60M143.72M154.07M216.41M
Operating Income -32.52M-63.47M--145.60M-143.72M-154.07M-216.41M
EBITDA ----143.45M-141.57M-151.47M-213.76M
Interest Expense -------
Pretax Income ----141.95M-134.24M-138.20M-206.69M
Tax Provision -------
Net Income -37.18M-63.41M--141.95M-134.24M-138.20M-206.69M
Diluted EPS ---3.40-2.60-1.77-1.01-
R&D Expense 24.52M49.27M100.07M112.50M113.76M119.45M184.70M

Compounded Sales Growth

5 Years:-
1 Year:-

Compounded Profit Growth

5 Years:-15.20%
1 Year:-

Stock Price Performance

1 Year:+165.69%
6 Months:+22.07%
3 Months:-3.21%
1 Month:-7.98%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -49.90M355.95M-285.10M297.67M350.07M277.57M
Current Assets ----248.10M263.86M316.46M242.19M
Cash & Equivalents 44.17M43.93M268.56M-140.02M225.11M49.50M162.05M
Inventory --------
Receivables ---0----
Total Liabilities -6.37M11.67M-53.90M47.12M56.97M65.92M
Current Liabilities -4.93M10.62M-22.36M17.93M30.51M42.63M
Long Term Debt --------
Total Debt ----32.86M31.36M28.97M26.20M
Total Equity -64.20M-100.45M344.28M-231.19M250.56M293.11M211.65M
Shares Outstanding ----47.72M78.37M109.38M149.36M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -28.36M-53.09M--116.31M-121.14M-118.01M-186.36M
Investing Cash Flow -267.00K-83.16M-58.44M70.70M-218.80M190.05M
Financing Cash Flow 28.39M360.88M-122.91M135.52M161.21M108.86M
Capital Expenditure -267.00K-464.00K--6.53M-193.00K-15.00K-137.00K
Free Cash Flow -28.62M-53.55M--122.83M-121.33M-118.02M-186.49M
Net Change in Cash ---65.04M85.08M-175.60M112.55M

Ratios (Annual)

Figures in %.

Metric Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------
Operating Margin % -------
Net Margin % -------
ROE % 37.0%-18.4%--61.4%-53.6%-47.2%-97.7%
ROCE % -72.3%-18.4%--55.4%-51.4%-48.2%-92.1%

Shareholding Pattern

Insiders
0.47%
Institutions
102.70%
Public Float
103.19%

Top Institutional Holders

#Holder% HeldSharesValue
1 Redmile Group, LLC 8.88% 14.55M $78.86M
2 Blackrock Inc. 6.68% 10.94M $59.29M
3 FMR, LLC 6.49% 10.64M $57.65M
4 BVF Inc. 5.31% 8.70M $47.14M
5 State Street Corporation 4.22% 6.92M $37.50M
6 Vanguard Capital Management LLC 3.64% 5.96M $32.28M
7 Bain Capital Life Sciences Investors, LLC 3.18% 5.21M $28.25M
8 Bellevue Group AG 3.15% 5.16M $27.95M
9 MAK Capital One LLC 2.88% 4.72M $25.60M
10 Adage Capital Partners GP L.L.C. 2.62% 4.30M $23.31M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ANNX

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space